ArticleFrontiers in neurology2020
Effects of Levodopa on Impairments to High-Level Vision in Parkinson's Disease.
Article in Frontiers in neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Alzheimer's Biomarkers and Visuospatial Cognition in Parkinson's Disease: Modification by α-Synuclein and Mediation of Age Effects.Movement disorders clinical practice · 2026Article
- Impact of levodopa and deep brain stimulation on visual impairments in Parkinson's disease.Clinical parkinsonism & related disorders · 2025Article
- Approach to Cognitive Impairment in Parkinson's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies have reported that Parkinson's disease (PD) is associated with impairments on cognitive visual tasks. However, the effects of dopamine on cognitive vision remain equivocal. The purpose of this study was to examine performance on cognitive vision tasks in persons with PD and the effects of levodopa on these tasks. Fourteen individuals with PD and 14 age- and sex-matched healthy older adults completed the study. Participants with PD completed the visual tasks following a 12-h withdrawal of dopaminergic medication and again 1 h after taking 1.5 times their normal dose of levodopa. Healthy older adults completed the visual tasks twice using the same session format. Five complex visual tasks were completed, including line discrimination, object discrimination, facial discrimination, visual working memory, and object rotation. The Unified Parkinson's Disease Rating Scale was also collected off and on medication. Participants with PD performed significantly worse than the healthy older adults across all five visual tasks. There were no significant differences in performance between the off and on medication state in persons with PD. This finding indicates either that dopamine deficiency may not be responsible for cognitive visual impairments in PD or that cognitive visual impairments in PD might simply be the result of deficits in more basic visual processing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.